UNSPSC 51402300: Tranquilizers and antimanic and antianxiety piperazines

Tranquilizers and antimanic and antianxiety drugs made from organic compounds composed of a six-membered ring containing two nitrogen atoms at opposite positions (hexa-hydro-pyrazine(s)).

UNSPSC 51402300 Tranquilizers and antimanic and antianxiety piperazines is a Class code that does not align with the recent state and local opportunities posted under it. The three recent solicitations—Seminole County's procurement of naloxone and drug deactivation systems, Texas HHS's Request for Information on direct-to-manufacturer prescriptions, and Minnesota MMCAP's RFP for generic multi-source pharmaceuticals and OTC products—address pharmaceutical supply, distribution, and benefit-management infrastructure rather than the specific drug compounds the code nominates. The naloxone solicitation concerns an opioid antagonist outside the piperazine family; the Texas RFI and Minnesota MMCAP opportunity target broader pharmacy benefit program administration and generic pharmaceutical procurement spanning multiple therapeutic classes. State and local buyers posting under this code appear to be county health departments, state health and human services agencies, and cooperative purchasing alliances seeking pharmaceutical products and services, but the recent-opportunities block does not support that these jurisdictions are actively procuring the specific tranquilizer or antianxiety compounds the code describes.

Geographic activity centers on Florida (Seminole County), Texas (Texas HHS), and Minnesota (MMCAP, serving Minnesota and Oregon participants). The issuing bodies span county-level health procurement (Seminole County, Florida), state health authorities (Texas Health and Human Services Commission), and multistate cooperative purchasing vehicles (Minnesota MMCAP). Seminole County's IFB (Solicitation IFB60459723LAS, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; Texas HHS's RFI (HHS0017013, posted April 3, 2026) gathered vendor capabilities for direct-to-manufacturer prescription contracting; and Minnesota MMCAP's RFP (S1070000015802, due March 26, 2026) established multiple contracts for generic pharmaceuticals and OTC products to be distributed through authorized wholesalers AmerisourceBergen, Cardinal Health, and Morris & Dickson, effective July 1, 2026. The code shows little relevant recent activity tied to the specific therapeutic compounds it nominates.